granted the underwriters an option for 30 days from the date of this prospectus to purchase up to 712,500 additional shares of our common stock at the public offering price, less the underwriting discounts and commissions, to cover over-allotments.Certain of our principal stockholders and/or their affiliates have indicated an interest in purchasing up to an aggregate of
life sciences company focused on the discovery, development and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that we identify.
subject to regulatory clearance or approval, through various channels, including through leading diagnostic instrument manufacturers that will offer our tests as novel assays on their instruments.Our lead product, the BGM Galectin-3 test for heart failure, measures galectin-3 levels in blood plasma or serum.
us through certified clinical laboratories and sales of automated versions of our diagnostic tests through leading diagnostic instrument manufacturers for use on their instruments.We believe that our solution offers several important benefits over existing approaches in diagnostics by:ØEnabling us to structure a discovery process for high-value market opportunities.We believe that our proprietary technology platform
offers us an opportunity to initiate a structured process for discovering biomarkers for high-value market opportunities that we identify.ØProviding novel tests for use on laboratory instruments.We are focused on discovering, developing and commercializing biomarker-based
service marks, trade names, logos and brand names identified in this prospectus are the property of their respective owners.4Table of ContentsThe offeringCommon stock offered by us4,750,000 sharesCommon stock to be outstanding after this offering18,143,607 sharesOver-allotment option712,500 sharesUse of proceedsWe intend to use the net proceeds of this offering to fund: the commercial launch of our lead product, BGM Galectin-3, including establishing a commercial organization and infrastructure; the
development, potential regulatory submission and potential commercial launch activities for our other diagnostic product candidates, including our galectin-3 test to identify patients at elevated risk for heart failure following a heart attack,
this offering at an exercise price of $5.35 per share and based upon the expected initial public offering price of $7.00 per share.Unless otherwise indicated, the information we present in this prospectus, including the information above:Øreflects the conversion of all of our outstanding preferred stock into 9,541,931 shares of our common stock immediately prior to completion of this
bridge notes issued pursuant to the agreement described below based upon the expected initial public offering price of $7.00 per share;Øassumes no exercise of the underwriters’ over-allotment option to purchase up to an additional 712,500 shares of our common stock; andØreflects the effectiveness of our restated certificate of incorporation and restated bylaws upon completion of this offering.In addition, unless otherwise indicated, all information in this prospectus gives effect to a 1-for-1.6667 reverse split of
Following the closing of this offering, the actual shares of common stock to be issued will be based on the amount of accrued interest then outstanding and the actual initial public offering price.Certain of our principal stockholders and/or their affiliates, including Flagship Ventures, or Flagship, Gilde Europe Food & Agribusiness Fund B.V.,
consolidated financial statements and includes an explanatory paragraph relating to substantial doubt about our ability to continue as a going concern.Years ended December 31,Nine months endedSeptember 30,Consolidated statements ofoperations data:20072008200920092010(in thousands, except share and per share amounts)Revenue$8,982$14,580$8,490$8,117$620Operating expenses:Cost of revenue7,30113,8228,4317,902650Research and development5,8326,8588,5276,5025,596Selling, general and administrative3,8204,4757,5205,5416,224Costs related to abandoned stock offering3,154————Gain on sale of property and equipment(118)————Total operating expenses19,98925,15524,47819,94512,470Loss from operations(11,007)(10,575)(15,988)(11,828)(11,850)Interest income3024221211024Interest expense(1)(689)(4,921)(244)(203)(1,964)Other income (expense)——(26)29(29)Net loss(11,394)(15,074)(16,137)(11,900)(13,839)Accretion of redeemable convertible preferred stock(368)(872)(977)(727)(769)Net loss attributable to common stockholders$(11,762)$(15,946)$(17,114)$(12,627)$(14,608)Net loss attributable to common stockholders per share — basic and diluted$(4.14)$(5.52)$(5.84)$(4.32)$(4.93)Weighted-average common shares outstanding used in computing per share amounts — basic and diluted2,843,7732,889,5132,930,8182,925,1312,963,626Pro forma net loss attributable to common stockholders per share — basic and diluted(2)$(1.29)$(1.11)Pro forma weighted-average common shares outstanding used in computing per share amounts — basic and diluted(2)12,472,74912,505,557footnotes
operations totaling approximately $650,000; and (iv) the issuance of 857,127 shares of our common stock upon the automatic conversion of $6.0 million in principal amount of outstanding bridge notes upon the completion of this offering based upon the
formaas adjusted(1)(unaudited)(in thousands)Cash, cash equivalents and marketable securities$2,855$4,855$34,948Deferred offering costs1,4841,484—Total assets5,9697,96936,578Warrant liability5094646Long-term debt, including current portion4,509388388Total liabilities9,0084,4244,424Redeemable convertible preferred stock71,828——Convertible preferred stock1,708——Accumulated deficit(92,415)(93,065)(93,065)Total stockholders’ (deficit) equity(74,867)3,54532,154(1)Each $1.00 increase or decrease in the expected initial public offering price of $7.00 per share would increase or decrease, as applicable, our pro forma as
If we fail to develop and commercialize diagnostic products, we may be unable to execute our business plan.Historically, we have generated revenue from initiatives, collaborations and biomarker discovery and analysis services agreements with pharmaceutical companies and healthcare organizations.
business strategy, however, focuses on discovering, developing and commercializing diagnostic products and services based on biomarkers, and we do not expect to continue to receive significant revenue from performing biomarker discovery and analysis
of our galectin-3 test or in achieving significant product revenue, or if we encounter other unforeseen adverse business developments, we may exhaust our capital resources prior to this time.14Table of ContentsRisk factorsWe cannot be certain that additional capital will be available when needed or that our actual cash
failure, we may not obtain regulatory clearance for the automated version of this test or for our other diagnostic product candidates when expected, if at all.In the United States, we intend to seek FDA clearance or approval for all of our products prior to their launch for clinical use, whether offered as a diagnostic kit or laboratory service.
for our automated galectin-3 test and our other product candidates in development, or our failure to obtain such clearances or approvals at all, would have a material adverse effect on our business, financial condition and results of operations.To market our products in Europe, we must obtain CE mark and may, in some cases, need marketing approval from the European Medicines Agency.
Some of the many factors that may cause the market price of our common stock to fluctuate include:Øour ability to commercialize the products, if any, that we are able to develop;Øthe progress and results of our biomarker discovery and product candidate development efforts;Øactions taken by regulatory authorities with respect to our product candidates, or our sales and marketing activities;Øregulatory developments in the United States, the European Union and other jurisdictions;Øthe outcome of legal actions to which we may become a party;Øannouncements concerning product development results or intellectual property rights of others;Øannouncements of technological innovations or new products by us or our competitors;Øchanges in financial estimates or recommendations by securities analysts;Øchanges in our capital structure, such as future issuances of securities or the incurrence of additional debt;Ørestatements of our financial results and/or material weaknesses in our internal controls;26Table of ContentsRisk factorsØpublication of research reports about us or the diagnostic products industry by securities or industry analysts;Øfluctuations in our operating results; andØdeviations in our operating results from the estimates of securities analysts or other analyst comments.The stock markets, and the markets for medical diagnostics and biotechnology stocks in particular, have experienced volatility that has often been
Market, the Securities and Exchange Commission or other regulatory authorities, which would entail expenditure of additional financial and management resources.The ownership of our common stock will continue to be highly concentrated and your interests may conflict with the interests of our existing stockholders.Certain of our principal stockholders and/or their affiliates, including Flagship, Gilde, GE, Legg Mason, SMALLCAP and Stelios Papadopoulos, have
interests in purchasing, the aggregate number of shares controlled by our executive officers, directors and current holders of more than 5% of our outstanding common stock, together with their affiliates and related persons, will represent
expected initial public offering price of $7.00 per share, the $6.0 million in principal amount of outstanding bridge notes will convert into approximately 857,127 shares of our common stock, which are included in the percentages set forth above.
intend to use the net proceeds of this offering to, among other things, finance working capital needs, including the commercialization of our galectin-3 diagnostic test and the continued development of our product candidates, as well as to fund
In addition, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.A significant portion of our total outstanding shares of common stock is restricted from immediate resale but may be sold into the market in the near future.
agreements;Øour ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;Øthe expected timing, progress or success of our research and development and any commercialization efforts;Øour ability to successfully obtain sufficient supplies of samples for our biomarker discovery and development efforts; andØour estimates regarding anticipated operating losses, future revenue, expenses, capital requirements and our needs for additional financing.In some cases, you can identify forward looking statements by terms such as “anticipates,” “believes,”
issuance of 857,127 shares of our common stock upon the automatic conversion of $6.0 million in principal amount of outstanding bridge notes upon the completion of this offering based upon the expected initial public offering price of $7.00 per
purposes only and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of the offering determined at pricing.34Table of ContentsCapitalizationAs of September 30, 2010ActualPro formaPro formaas adjusted(in thousands)Cash, cash equivalents and marketable securities$2,855$4,855$34,948Long-term debt, including current portion$4,509$388$388Warrant liability5094646Redeemable convertible preferred stock:Series A redeemable preferred stock; $0.001 par value, 16,017,067 shares authorized; 15,823,566 shares issued and outstanding,
unqualified opinion on the consolidated financial statements and includes an explanatory paragraph relating to substantial doubt about our ability to continue as a going concern.Years ended December 31,Nine Months EndedSeptember 30,Consolidated statements ofoperations data:2005200620072008200920092010(in thousands, except share and per share data)Revenue$1,532$6,046$8,982$14,580$8,490$8,117$620Operating expenses:Cost of revenue—2,4577,30113,8228,4317,902650Research and development7,1315,3315,8326,8588,5276,5025,596Selling, general and administrative2,4122,4503,8204,4757,5205,5416,224Costs related to abandoned stock offering——3,154————Gain on sale of property and equipment(307)—(118)————Total operating expenses9,23610,23819,98925,15524,47819,94512,470Loss from operations(7,704)(4,192)(11,007)(10,575)(15,988)(11,828)(11,850)Gain on extinguishment of debt1,035——————Interest income22243024221211024Interest expense(1)(1,585)(574)(689)(4,921)(244)(203)(1,964)Other income (expense)————(26)29(29)Net loss(8,232)(4,742)(11,394)(15,074)(16,137)(11,900)(13,839)Accretion of redeemable convertible preferred stock——(368)(872)(977)(727)(769)Net loss attributable to common stockholders$(8,232)$(4,742)$(11,762)$(15,946)$(17,114)$(12,627)$(14,608)Net loss attributable to common stockholders per share —basic and diluted$(2.92)$(1.68)$(4.14)$(5.52)$(5.84)$(4.32)$(4.93)39Table of ContentsSelected consolidated financial informationYears ended December 31,Nine Months EndedSeptember 30,Consolidated statementsof operations data:2005200620072008200920092010(in thousands, except share and per share data)Weighted-average common shares outstanding used in computing per share amounts — basic and diluted2,815,4682,817,1022,843,7732,889,5132,930,8182,925,1312,963,626Pro forma net loss attributable to common stockholders per share — basic and diluted(2)$(1.29)$(1.11)Pro forma weighted-average common shares outstanding used in computing per share amounts — basic and diluted(2)12,472,74912,505,557(1)Interest expense in 2008 and in the nine months ended September 30, 2010 includes non-cash charges of $4.0 million and $1.7 million, respectively,
at the beginning of the period.As of December 31,As of September 30,Consolidated balancesheet data:200520062007200820092010(in thousands)Cash, cash equivalents and marketable securities$1,148$1,010$1,214$24,302$10,393$2,855Deferred offering costs————651,484Total assets3,1036,1698,78035,21712,6255,969Warrant liability———445471509Long-term debt and capital leases, including current portion5,0881,3104,4782,4651,2524,509Total liabilities11,4869,91816,33014,2995,4679,008Redeemable convertible preferred stock19,97128,73531,03570,08271,05971,828Convertible preferred stock1,7081,7081,7081,7081,7081,708Accumulated deficit(31,229)(35,971)(47,365)(62,439)(78,576)(92,415)Total stockholders’ (deficit)(28,354)(32,484)(38,585)(49,164)(63,901)(74,867)40Table of ContentsManagement’s discussion and analysis of financial condition and results of operationsYou should read the following in conjunction with the “Selected consolidated financial information” and our consolidated financial statements and the related notes thereto that appear
statements” included elsewhere in this prospectus.OVERVIEWWe are a life sciences company focused on the discovery, development and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that we identify.
diagnostic product candidates, we expect our research and development, sales and marketing, and general and administrative expenses to increase significantly.During the nine months ended September 30, 2010, we incurred a net loss totaling $13.8 million and used cash in operating activities totaling $9.4 million.
securities or the terms of the stock option, we may be required to accelerate, increase or cancel any remaining unamortized stock-based compensation expense.We also account for equity instruments issued to our non-employee directors and consultants at fair value.
grant, taking into account various objective and subjective factors.(2)The per share estimated fair value of options was estimated for the date of grant using the Black-Scholes options pricing model.Based upon the expected initial public offering price set forth on the cover of this prospectus, the aggregate intrinsic value of our outstanding stock
in July 2008;Øthe liquidation preferences of our preferred stock, including any additional fundraising activities that may have occurred in the period;46Table of ContentsManagement’s discussion and analysis of financial condition and results of operationsØthe illiquid nature of our common stock, including the opportunity and timing for any expected liquidity events;Øour size and historical operating and financial performance, including our recent operating and financial projections as of each grant date;Øachievement of enterprise milestones;Øthe market value of a peer group comprised of selected publicly-traded companies and guideline transactions identified as being comparable to us; andØmarket conditions for early-stage diagnostic companies and other life science companies.Our board of directors considered and applied these and other factors in determining an estimate of the fair value of our common stock on each stock
consideration the following scenarios:Øtwo different scenarios for the completion of an initial public offering – a short-term view (6 months) and a long-term view (18 months or more);Øa sale to a strategic acquirer at a significant premium to the liquidation preference;Øa sale to a strategic acquirer at a premium to the liquidation preference; andØa sale to an acquirer below the liquidation preference.The valuation methodology our board of directors considered to determine the fair value of our common stock was based on the probability-weighted expected return method, liquidation preferences, progress
The fair value of our common stock through June 30, 2009 also reflected the following factors:Øthe submission of our 510(k) premarket notification with the FDA for the clearance of our galectin-3 diagnostic test (March 2009);Øadditions to our senior management team (January - June 2009);Øsignificant deterioration in the U.S. economy and the valuations of comparable companies; andØsignificant deterioration in the prospects for the funding of early stage companies such as ours.47Table of ContentsManagement’s discussion and analysis of financial condition and results of operationsThe fair value of our common stock was determined to be $9.45 per share as of November 25, 2009.
as follows:Years ended December 31,Nine months endedSeptember 30,2010200720082009Research and development expenses$884$452$565$375Selling, general and administrative expenses1,0261,1521,816$1,363Total$1,910$1,604$2,381$1,738Stock-based compensation expense of approximately $3.0 million was unrecognized for non-vested awards as of September
Revenue from the HRP initiative in 2008 was $12.1 million, or 83% of total revenue, compared with $5.1 million, or 57% of total revenue, in 2007.51Table of ContentsManagement’s discussion and analysis of financial condition and results of operationsOperating expensesThe following table sets forth certain information concerning our operating expenses for the periods shown:Years endedDecember 31,Change20072008($)(%)(in thousands)Cost of revenue$7,301$13,822$6,52189%Research and development5,8326,8581,02618Selling, general and administrative3,8204,47565517Costs related to abandoned stock offering3,154—(3,154)(100)Gain on sale of property and equipment(118)—118(100)Total operating expenses$19,989$25,155$5,16626%Cost of revenue.
from this offering, together with our existing cash, cash equivalents and marketable securities (including the proceeds from our bridge note financing in November 2010), will be sufficient to meet our anticipated cash requirements through 2012.If we are not able to generate significant revenues from sales of our galectin-3 tests by the end of 2012, we will need to raise funds,
Our future liquidity and capital funding requirements will depend on numerous factors, including:Øthe rate of progress and cost of our commercialization activities;Øthe success of our research and development efforts;Øthe expenses we incur in marketing and selling our products;Øthe revenue generated by sales of any future products;Øthe emergence of competing or complementary products;55Table of ContentsManagement’s discussion and analysis of financial condition and results of operationsØthe costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; andØthe terms and timing of any collaborative, licensing or other arrangements that we have or may establish.Contractual obligations and commitmentsThe
the event we commercialize blood-based biomarker diagnostic products under this partnership, we will be required to make certain payments to Humana based on such products.The agreement has an initial three-year term and automatically renews for an additional period of 12 months unless either party gives not less than 120 days written notice of termination to the other
appointment to the board of directors, new non-employee directors receive a non-qualified stock option to purchase 8,410 shares of our common stock at an exercise price equal to the fair market value on the date of grant that vests one year from the
shares of our common stock upon the automatic conversion of $6.0 million in principal amount of the outstanding bridge notes upon the completion of this offering, all of which are based upon the expected initial public offering price of $7.00 per
Based upon an expected initial public offering price of $7.00 per share, the $2.0 million in principal amount of the outstanding bridge notes will convert into approximately 285,709 shares of our common stock.
Based upon an expected initial public offering price of $7.00 per share, the $2.0 million in principal amount of the outstanding bridge notes will convert into approximately 285,709 shares of our common stock.